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Objective: To report our experiences with 40 patients who were treated with magnetic resonance-guided
focused ultrasound surgery (MRgFUS) for uterine ﬁbroids and their 6-month follow-up status.
Materials and Methods: A total of 40 patients with uterine ﬁbroids underwent MRgFUS from January
2009 to November 2011. The Uterine Fibroid Symptoms and Quality of Life Questionnaire was used to
determine the patients' Symptom Severity Scores (SSS) prior to and 6 months after treatment. The
nonperfused volume (NPV) values and NPV ratio were obtained immediately at the end of the treatment
and at 6 months follow-up.
Results: No procedure-related complications were noted throughout the 6-month follow-up period
among the 40 patients who underwent MRgFUS for uterine ﬁbroids. The mean reduction in SSS in our
patients after 6 months was 43.7%, and the mean reduction of ﬁbroid volume was 31.7%. In addition, the
mean reduction of NPV and mean NPV ratio was 52.7% and 33.3%, respectively.
Conclusion: The results obtained from this study demonstrated that MRgFUS can be safely and effectively
used to ablate uterine ﬁbroids to produce a signiﬁcant decrease in mean ﬁbroid volume and improve SSS
for up to 6 months after treatment.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Uterine leiomyomas (ﬁbroids) are the most common benign
neoplasm that can occur in reproductive-age women. About
20e50% of reproductive-age women have uterine myoma,
whereas many women do not experience any problems. About
10% of reproductive-age women with myoma suffer from
symptoms that affect their quality of life. Generally, ﬁbroids have
been identiﬁed clinically in at least 25% of women [1]. Further-
more, pathologic analysis suggests that the prevalence of ﬁbroids
may be as high as 77% [2,3]. In the past, surgical procedures such
as myomectomy or hysterectomy were the traditional treatment
for symptomatic uterine myoma. However, more and more
women have chosen not to undergo invasive treatments because
of postoperative complications. In 2004, the United States Food
and Drug Administration approved magnetic resonance-guidedtic Radiology, Cardinal Tien
istrict, New Taipei City 231,
bstetrics & Gynecology. Publishedfocused ultrasound ablation (MRgFUA), the least invasive ther-
apy for uterine myoma aside from oral therapy. Since then,
MRgFUA has been used worldwide to treat symptomatic uterine
myomas [4e6].
Focused ultrasound generates heat by focusing ultrasound
waves to ablate tissue only at the focal point. This effect is similar to
a magnifying glass that uses focused sunlight to burn a leaf. The
high-intensity ultrasound deposits localized energy, causing rapid
vibration of molecules within the focal spot, where the focal point
temperature can rise to 60e80C, resulting in thermal ablation
within a small tissue region (about 1e2mL). After repeating several
adjacent small region ablations, larger volumes of ablation can be
performed gradually. The required number of sonications and the
length of the treatment depend on the size of the ﬁbroid. The time
required for the entire magnetic resonance-guided focused ultra-
sound surgery (MRgFUS) ranges from 2 to 3 hours. This noninvasive
procedure is a new treatment for uterine ﬁbroid, because more and
more patients do not wish undergo any surgical incision, puncture
of the uterus, anesthesia, or radiation exposure [7]. Many reports
from the United States, Europe, Japan, and Korea have conﬁrmed
the safety and effectiveness of the procedure, and it is consideredby Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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the surrounding tissue unharmed [8,9].
In Taiwan, there is less experience of using MRgFUS in treating
uterine myoma in recent years when compared to other countries.
This paper demonstrates our experiences and the result of a 6-
month follow-up of 40 patients (from January 2009 to November
2011), who underwent MRgFUS treatment for uterine myoma.Materials and methods
From January 2009 to November 2011, a total of 400 patients
sought MRgFUS treatment for their symptomatic uterine ﬁbroids in
our hospital. All patients were required to complete the Symptom
Severity Score (SSS) and Uterine Fibroid Symptoms and Quality of
Life (UFS-QOL) questionnaires [10] (Table 1) for the assessment of
uterine ﬁbroid symptoms. These patients underwent initial mag-
netic resonance imaging (MRI) scans for ﬁbroid screening using a
1.5-T MRI scanner (GE Medical Systems, Milwaukee, WI, USA) with
T1-weighted, T2-weighted, and enhanced T1-weighted (axial,
coronal, and sagittal) sequences. In this MRI screening, the exclu-
sion criteria were as follows: ﬁbroids larger than 10 cm or smaller
than 3 cm, ﬁbroid number is more than four, ﬁbroids located on the
subserosal layer of the uterus, ﬁbroids with hyperintensity (white
ﬁbroid) on T2-weighted images, necrotic ﬁbroids, extensive ade-
nomyosis, and extensive abdominal scar that obstructs the ultra-
sound beam path [3]. According to the screening MR images, 124
patients (31%) were suitable for MRgFUS treatment under our
criteria, of which only 40 patients (10%) chose to undergo MRgFUS
for ﬁbroids treatment.
During the treatment, the patient's lower abdomen was shaved
and cleaned to remove any hair. An intravenous (IV) line was set up
for administration of sedatives, and a urinary catheter was inserted
to empty the urinary bladder. The patient laid prone on the ExA-
blate 2000 treatment table (InSightec, Haifa, Israel), in which the
transducer is housed. The patient's legs may be wrapped with
compression stockings to reduce the risk of deep vein thrombosis.
Prior to treatment initiation, 10 mg diazepam per os and 2 mL
fentanyl via IV were given for sedation. The patient's blood pres-
sure, heart rate, oxygenation, and comfort level were monitored
throughout the treatment. The position of the patient over the
transducer is determined from the three-plane localizer, T2-
weighted image. To avoid ultrasound energy-sensitive regions
such as bone, bowel, and nerves, these regions were marked to
ensure safety (Figures 1A and 1B). At the end of the MRgFUS
ablation treatment, a series of contrast-enhanced T1-weighted
images were acquired to determine the treatment outcome,
where the treated ﬁbroid would be shown as a nonperfused area.Table 1
Symptom Severity Score (SSS) questionnaire.
During the previous 3 mo, how distressed were you by SSS
1 2 3 4 5
1. Heavy bleeding during your menstrual period
2. Passing blood clots during your menstrual period
3. Fluctuation in the duration of your menstrual period
compared to your previous cycle
4. Fluctuation in the length of your monthly cycle
compared to your previous cycle
5. Feeling tightness or pressure in your pelvic area
6. Frequent urination during the daytime hours
7. Frequent nighttime urination
8. Feeling fatigued
Total score
Scores: 1 ¼ not at all; 2 ¼ a little; 3 ¼ somewhat; 4 ¼ a great deal; 5 ¼ a very great
deal.The therapeutic effect was then determined by the change in
nonperfused volume (NPV) calculation. The NPV percentage of the
ﬁbroids was calculated as NPV divided by total ﬁbroid volume and
multiplied by 100 [3]. After these postprocedure assessments, the
patients were sent to a recovery room with their accompaniment
and may be discharged within an hour.
All patients were required to return for follow-up MRI exami-
nations, 6 months after the MRgFUS treatment. Prior to the follow-
up examinations, theywere asked to complete additional follow-up
SSS and UFS-QOL questionnaires as well. The total ﬁbroid volume
and the NPV change ratio were calculated using the same method
based on T2-weighted images and enhanced T1-weighted images.
Results
The mean age of the 40 patients was 41.9 ± 4.5 years (range,
35e51 years). No serious or unexpected adverse events occurred
during the 6-month-long study. All patients were followed up for
6 months, and no procedure-related complications were recorded
throughout this period. The SSS and UFS-QOL prior to and after
treatment for 6 months are shown in Table 2. The total ﬁbroid
volume and the NPV ratio prior to and after treatment for 6 months
are shown in Table 3 (Figures 2 and 3).
Discussion
Uterine ﬁbroid is a benign tumor that arises from the muscle
tissue of the uterus, and the size of the myoma varies from as large
as a melon to as small as a coin. Approximately 20e50% of
reproductive-age women develop uterine myoma, whereas many
women do not experience any similar symptoms that require
treatment. About 10% of reproductive-age women with myoma
have severe symptoms that affect their quality of life. For example,
the complication of a large myoma may cause very heavy and
prolonged menstrual periods, pain in the back of the legs, pelvic
pain or pressure, pain during sexual intercourse, constipation,
increased urinary frequency, incontinence, and the inability to
empty the bladder [3,11e13]. Sometimes, a woman with an
enlarged abdomen because of a large ﬁbroid would be mistakenly
assumed to have gained weight or to be pregnant. The patients
have several options for treatment for uterine ﬁbroid, including
hysterectomy, myomectomy (abdominal or laparoscopic), uterine
artery embolization, and hormonal therapy [14]. In addition, there
are imaging-guided ablation methods that destroy the structure of
myomas while sparing normal tissue; these include laser ablation,
cryoablation, radiofrequency ablation, and MRgFUS [15,16]. Each of
the treatments has its own beneﬁts and disadvantages, and each
one has varying degrees of invasiveness for the treatment of
symptomatic uterine ﬁbroids.
The combination of ultrasound and MRI (MRgFUS) provides an
alternative noninvasive treatment for uterine ﬁbroids. In a study
performed by Sapareto and Dewey [17], the tumoral tissue was
damaged when the thermal exposure is higher than the tissue's
thermal threshold. The 100% focal tissue damage of thermal
dosimetry is under 43C for 240 minutes of treatment duration
(timeetemperature relationship). The timeetemperature relation-
ship upon which this equivalent dose calculation is based does not
predict nor require that different tissues have the same sensitivity
to heat. So the equivalent thermal dosimetry for 100% tumoral
tissue damage is determined to be 54C for 3 seconds or 57C for
1 second [17]. High-intensity focused ultrasound waves are used to
noninvasively heat and thermally destroy the ﬁbroid, whereas
magnetic resonance imaging (MRI) provides anatomical imaging
guidance during treatment planning and is used in real time for
thermal monitoring during the treatment. Postprocedural MRI
Figure 1. (A) T2-weighted sagittal scan image. (B) T2-weighted axial scan image for preprocedure planning. The sensitive regions such as pubic bone, bowel and nerves (arrows)
were marked to ensure safety of MRgFUS ablation. a ¼ uterus; b ¼ uterine ﬁbroid; c ¼ urinary bladder; d ¼ pubic bone; e ¼ sacral nerve. MRgFUS ¼ magnetic resonance-guided
focused ultrasound surgery.
Table 2
SSS of patients prior to and 6 months after treatment.
Pre-MRgFUS Post-MRgFUS in 6 mo Change
SSS (8 questions) 62.2 ± 16.4 35.0 ± 9.5 43.7%
UFS-QOL (29 questions) 37.9 ± 15.8 57.0 ± 13.6 þ33.5%
MRgFUS¼magnetic resonance-guided focused ultrasound surgery; SSS¼ Symptom
Severity Score; UFS-QOL¼Uterine Fibroid Symptoms and Quality of Life
Questionnaire.
Table 3
Fibroid size, NPV, and NPV ratio of patients at baseline and 6months after treatment.
Pre-MRgFUS Post-MRgFUS in 6 mo Change
Size 258.1 ± 223.8 176.2 ± 164.2 31.7%
Nonperfused volume (NPV) 149.2 ± 112.7 70.6 ± 65.2 52.7%
NPV ratio 64.5 ± 11.4 43.0 ± 26.6 33.3%
MRgFUS ¼ magnetic resonance-guided focused ultrasound surgery;
NPV ¼ nonperfused volume.
Figure 2. (A) Pretreatment T2-weighted sagittal image of a 44-year-old woman demonstrat
is 40.6 and 64, respectively. (B) Posttreatment enhanced T1-weighted image of the patient
indicative of the posttreatment necrotic area. (C) The 6-month follow-up enhanced T1-we
decrease rate is 36.9%. The SSS and QOL is 9.3 and 89.7, respectively. The improvemen
SSS¼ Symptom Severity Score; UFS-QOL¼Uterine Fibroid Symptoms and Quality of Life Q
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ium contrast to determine the extent of MRgFUS treatment.
During MRgFUS therapy, the ultrasound beam is focused on the
ﬁbroid tissue, and because of the signiﬁcant energy deposited at the
focus (sonication), the temperature within the tissue rises to be-
tween 65C and 85C, destroying the ﬁbroid tissue via coagulation
necrosis [18]. This is the reason why the ﬁbroid volume decreased
signiﬁcantly in our study after 6 months. We suggest that the
reduction in ﬁbroid volume is closely associated with the
improvement of SSS (the SSS mean scores decreased from
62.2 ± 16.4 to 35.0 ± 9.5) and UFS-QOL (the UFS-QOL scores
improved from 37.9 ± 15.8 to 57.0 ± 13.6). We conclude that
MRgFUS is effective in reducing ﬁbroid volume and providing relief
for myoma symptoms. Furthermore, the ideal therapeutic effect of
the NPV ratio is 55 ± 25% immediately after treatment [19].
In this study, MRgFUS was determined to be effective in
improving symptom severity, 6 months after treatment. The
average SSS prior to the treatment was 62.2 ± 16.4. The SSS reduced
to 35.0 ± 9.5 at 6 months after the treatment. The mean reductioning one uterine ﬁbroid (arrow) measuring about 97 mL (volume). Her SSS and UFS-QOL
demonstrating the resulting NPV ratio (53.6%). The low signal intensity area (arrow) is
ighted image demonstrating the volume of ﬁbroid decreased to 61.2 mL. The volume
t of SSS and UFS-QOL is 31.3 and 25.7, respectively. NPV ¼ nonperfused volume;
uestionnaire.
Figure 3. (A) Pretreatment T2-weighted sagittal image of a 47-year-old woman demonstrating one uterine ﬁbroid (arrow) measuring about 150.2 mL (volume). Her SSS and UFS-
QOL is 53.1 and 29.3, respectively. (B) The posttreatment enhanced T1-weighted image of the patient demonstrating the resulting NPV ratio (66.7%). The low signal intensity area
(arrow) is indicative of the posttreatment necrotic area. (C) The 6-month follow-up enhanced T1-weighted image demonstrating that the volume of ﬁbroid decreased to 89.3 mL.
The volume decrease rate is 40.5%. The SSS and QOL is 37 and 61, respectively. The improvement of SSS and UFS-QOL is 16.1 and 31.7, respectively. NPV ¼ nonperfused volume;
SSS¼ Symptom Severity Score; UFS-QOL¼Uterine Fibroid Symptoms and Quality of Life Questionnaire.
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is similar to the results reported by earlier studies [20e22]. In
addition, the mean ﬁbroid volume was reduced from 258.1 to
176.2 mL (31.7% reduction rate), and the mean NPV was reduced
from 149.2 to 70.6 mL (52.7%) (Table 3). These results are also very
similar to previous published results [23e25]. These results
demonstrate that MRgFUS is an effective method for the selective
ablation of tissue within the uterus, and this noninvasive treatment
may be offered as an alternative therapy for women with uterine
ﬁbroids.
This is the ﬁrst retrospective study of MRgFUS for treatment of
uterine ﬁbroids in Taiwan. Our results demonstrated that MRgFUS
can be safely and effectively used to ablate sufﬁcient uterine ﬁ-
broids to produce a decrease in mean ﬁbroid volume and signiﬁ-
cantly improve SSS for up to 6 months. However, further
investigation is still required to determine the potential fertility
impact and pregnancy outcome of these patients in the future.Conﬂict of interest
The authors have no conﬂicts of interest relevant to this article.References
[1] Buttram Jr VC, Reiter RC. Uterine leiomyomata: etiology, symptomatology,
and management. Fertil Steril 1981;36:433e45.
[2] Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol
1990;94:435e8.
[3] Lin Y-H, Leung Ting-Kai, Wang H-J, Kung CH, Hsiao HY, Ting YC, et al. Treat-
ment of uterine ﬁbroids by using magnetic resonance-guided focused ultra-
sound ablation: the initial experience in Taiwan. Chin J Radiol 2009;34:
263e71.
[4] Gedroyc WM, Anstee A. MR-guided focused ultrasound. Expert Rev Med De-
vices 2007;4:539e47.
[5] Munro MG. The evolution of uterine surgery. Clin Obstet Gynecol 2006;49:
713e21.
[6] Trumm CG, Napoli A, Peller M, Clevert DA, Stahl R, Reiser M, et al. MR-guided
focused ultrasound. Current and future applications. Radiologe 2013;53:
200e8.
[7] Hindley J, Gedroyc WM, Regan L, Stewart E, Tempany C, Hynyen K, et al. MRI
guidance of focused ultrasound therapy of uterine ﬁbroids: early results. AJR
Am J Roentgenol 2004;183:1713e9.
[8] Fennessy FM, Tempany CM, McDannold NJ, So MJ, Hesley G, Gostout B, et al.
Uterine leiomyomas: MR imaging-guided focused ultrasound surgerydresults
of different treatment protocols. Radiology 2007;243:885e93.[9] Stewart EA, Gostout B, Rabinovici J, Kim HS, Regan L, Tempany CM. Sustained
relief of leiomyoma symptoms by using focused ultrasound surgery. Obstet
Gynecol 2007;110:279e87.
[10] Spies JB, Coyne K, Guaou Guaou N, Boyle D, Skyrnarz-Murphy K,
Gonzalves SM. The UFS-QOL, a new disease-speciﬁc symptom and health-
related quality of life questionnaire for leiomyomata. Obstet Gynecol
2002;99:290e300.
[11] Akinyemi BO, Adewoye BR, Fakoya TA. Uterine ﬁbroid: a review. Niger J Med
2004;13:318e29.
[12] Falcone T, Bedaiwy MA. Minimally invasive management of uterine ﬁbroids.
Curr Opin Obstet Gynecol 2002;14:401e7.
[13] Middendorf K, Burges A, Strauss A, Hepp H. Uterine ﬁbroidsdtherapy from
the point of view of the gynaecologist. Radiologe 2003;43:615e23.
[14] deSouza NM, Williams AD. Uterine arterial embolization for leiomyomas:
perfusion and volume changes at MR imaging and relation to clinical
outcome. Radiology 2002;222:367e74.
[15] Funaki K, Fukunishi H, Funaki T, Sawada K, Kaji Y, Maruo T. Magnetic
resonance-guided focused ultrasound surgery for uterine ﬁbroids: relation-
ship between the therapeutic effects and signal intensity of preexisting T2-
weighted magnetic resonance images. Am J Obstet Gynecol 2007;196. 184
e1e6.
[16] Tempany CM, Stewart EA, McDannold N, Quade BJ, Jolesz FA, Hynynen K. MR
imaging-guided focused ultrasound surgery of uterine leiomyomas: a feasi-
bility study. Radiology 2003;226:897e905.
[17] Sapareto SA, Dewey WC. Thermal dose determination in cancer therapy. Int J
Radiat Oncol Biol Phys 1984;10:787e800.
[18] Cline HE, Hynynen K, Watkins RD, Adams WJ, Schenck JF, Ettinger RH, et al.
Focused US system for MR imaging-guided tumor ablation. Radiology
1995;194:731e7.
[19] LeBlang SD, Hoctor K, Steinberg FL. Leiomyoma shrinkage after MRI-
guided focused ultrasound treatment: report of 80 patients. AJR
2010;194:274e80.
[20] Harding G, Coyne KS, Thompson CL, Spies JB. The responsiveness of the
uterine ﬁbroid symptom and health-related quality of life questionnaire (UFS-
QOL). Health Qual Life Outcomes 2008;6:99.
[21] Smart OC, Hindley JT, Regan L, Gedroyc WG. Gonadotrophin-releasing hor-
mone and magnetic-resonance-guided ultrasound surgery for uterine leio-
myomata. Obstet Gynecol 2006 Jul;108:49e54.
[22] Yoon SW, Kim KA, Cha SH, Kim YM, Lee C, Na YJ, et al. Successful use of
magnetic resonance-guided focused ultrasound surgery to relieve symptoms
in a patient with symptomatic focal adenomyosis. Fertil Steril 2008;90. 2018
e13e5.
[23] Morita Y, Ito N, Hikida H, Takeuchi S, Nakamura K, Ohashi H. Non-invasive
magnetic resonance imaging-guided focused ultrasound treatment for uterine
ﬁbroids d early experience. Eur J Obstet Gynecol Reprod Biol 2008;139:
199e203.
[24] Okada A, Morita Y, Fukunishi H, Takeichi K, Murakami T. Non-invasive mag-
netic resonance-guided focused ultrasound treatment of uterine ﬁbroids in a
large Japanese population: impact of the learning curve on patient outcome.
Ultrasound Obstet Gynecol 2009;34:579e83.
[25] Ren XL, Zhou XD, Zhang J, He GB, Han ZH, Zheng MJ, et al. Extracorporeal
ablation of uterine ﬁbroids with high-intensity focused ultrasound: imaging
and histopathologic evaluation. J Ultrasound Med 2007;26:201e12.
